nach oben

Drugs & Aging

Erschienen in:

01.03.2009 | Review Article

Secondary Stroke Prevention Strategies for the Oldest Patients

Possibilities and Challenges

verfasst von: Cheryl D. Bushnell, Cathleen S. Colón-Emeric

Erschienen in: Drugs & Aging | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Older adults are not only at higher risk of experiencing stroke, but also have multiple co-morbidities that make treatment for secondary stroke prevention challenging. Very few clinical trials specifically related to secondary stroke prevention treatment efficacy have focused on the oldest-old (≥85 years) and, therefore, evidence-based recommendations for treatment specific to this population are not available. Some of the special considerations for stroke prevention treatments in older patients include careful titration of blood-pressure-lowering drugs to avoid hypotension, the risk of haemorrhagic stroke with HMG-CoA reductase inhibitors (statins) and weighing the risk of recurrent ischaemia versus bleeding in patients taking antiplatelet or anticoagulant therapy. The risk of peri-procedural complications appears to be high with both carotid angioplasty and stenting and carotid endarterectomy in older patients with carotid stenosis. Other common issues in older patients include adverse drug events, recognizing the risk of dementia, depression and osteoporosis and deciding when to discontinue secondary stroke prevention. In this review, we provide the practitioner with the evidence related to specific approaches to secondary stroke prevention in older patients, and identify the knowledge gaps that currently limit our ability to appropriately treat this vulnerable population.

Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics — 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117(4): e25–146PubMedCrossRef

Muntner P, Garrett E, Klag MJ, et al. Trends in stroke prevalence between 1973 and 1991 in the US population 25 to 74 years of age. Stroke 2002; 33(5): 1209–13PubMedCrossRef

Kaplan RC, Tirschwell DL, Longstreth Jr WT, et al. Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. Neurology 2005; 65(6): 835–42PubMedCrossRef

Clark TG, Murphy MF, Rothwell PM. Long term risks of stroke, myocardial infarction, and vascular death in “low risk” patients with a non-recent transient ischae-mic attack. J Neurol Neurosurg Psychiatry 2003; 74(5): 577–80PubMedCrossRef

Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services [abstract]. BMJ 2004; 328(7435): 326PubMedCrossRef

van Wijk I, Kappelle LJ, van Gijn J, et al. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 2005; 365(9477): 2098–104PubMedCrossRef

Touze E, Varenne O, Chatellier G, et al. Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and metaanalysis. Stroke 2005; 36(12): 2748–55PubMedCrossRef

Hardie K, Hankey GJ, Jamrozik K, et al. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 2004; 35(3): 731–5PubMedCrossRef

Samsa G, Bian J, Lipscomb J, et al. Epidemiology of recurrent cerebral infarction: a Medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke 1999; 30: 338–49PubMedCrossRef

10.

Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295(2): 180–9PubMedCrossRef

11.

Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Long-term disability after first-ever stroke and related prognostic factors in the Perth Community Stroke Study, 1989–1990. Stroke 2002; 33(4): 1034–40PubMedCrossRef

12.

Hankey GJ, Spiesser J, Hakimi Z, et al. Time frame and predictors of recovery from disability following recurrent ischemic stroke. Neurology 2007; 68(3): 202–5PubMedCrossRef

13.

Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke 2008; 39: 1647–52PubMedCrossRef

14.

Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37(2): 577–617PubMedCrossRef

15.

Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest 2008; 133: 630–69CrossRef

16.

Guyatt G, Schunemann HJ, Cook D, et al. Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 179S–87SPubMedCrossRef

17.

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033–41

18.

Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338(8778): 1281–5PubMedCrossRef

19.

Perry Jr HM, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000; 284(4): 465–71PubMedCrossRef

20.

Bulpitt CJ, Beckett NS, Cooke J, et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21(12): 2409–17PubMedCrossRef

21.

Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358(18): 1887–98PubMedCrossRef

22.

Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363(9411): 757–67PubMedCrossRef

23.

Amarenco P, Bogousslavsky J, Callahan 3rd A, et al. Highdose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355(6): 549–59PubMedCrossRef

24.

Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360(9346): 1623–30PubMedCrossRef

25.

Hey-Hadavi JH, Kuntze E, Luo D, et al. Tolerability of atorvastatin in a population aged > or=65 years: a retrospective pooled analysis of results from fifty randomized clinical trials. Am J Geriatr Pharmacother 2006; 4(2): 112–22PubMedCrossRef

26.

CAPRIE Study Group. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348(9038): 1329–39CrossRef

27.

Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and Clopidogrel compared with Clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364(9431): 331–7PubMedCrossRef

28.

Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354(16): 1706–17PubMedCrossRef

29.

Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study: II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143(1–2): 1–13PubMedCrossRef

30.

Halkes PH, van Gijn J, Kappelle LJ, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367(9523): 1665–73PubMedCrossRef

31.

Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipyridamole versus Clopidogrel for recurrent stroke. N Engl J Med 2008; 359(12): 1238–51PubMedCrossRef

32.

Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35(3): 776–85PubMedCrossRef

33.

Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206–52PubMedCrossRef

34.

Chalmers J, MacMahon S. Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS): interpretation and implementation. J Hypertens Suppl 2003; 21(5): S9–14PubMed

35.

SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265(24): 3255–64CrossRef

36.

Staessen JA, Fagard R, Thijs L, et al. Subgroup and perprotocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Arch Intern Med 1998; 158(15): 1681–91PubMedCrossRef

37.

Bulpitt C, Fletcher A, Beckett N, et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging 2001; 18(3): 151–64PubMedCrossRef

38.

Nilsson PM. Reducing the risk of stroke in elderly patients with hypertension: a critical review of the efficacy of antihypertensive drugs. Drugs Aging 2005; 22(6): 517–24PubMedCrossRef

39.

Oates DJ, Berlowitz DR, Glickman ME, et al. Blood pressure and survival in the oldest old. J Am Geriatr Soc 2007; 55(3): 383–8PubMedCrossRef

40.

Amarenco P, Tonkin AM. Statins for stroke prevention: disappointment and hope. Circulation 2004; 109 (23 Suppl. 1): III44–9PubMedCrossRef

41.

Gorelick PB. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review. Stroke 2002; 33(3): 862–75PubMedCrossRef

42.

MRC/BHF Heart Protection Study of cholesterol lowering !with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7–22

43.

4S Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov 19; 344(8934): 1383–9

44.

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339(19): 1349–57CrossRef

45.

Amarenco P, Labreuche J, Lavallee P, et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35(12): 2902–9PubMedCrossRef

46.

Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685–96PubMedCrossRef

47.

Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 1999; 99(2): 216–23PubMedCrossRef

48.

Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149–58PubMedCrossRef

49.

National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143–421

50.

Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008; 70: 2364–70PubMedCrossRef

51.

Eaton CB, Lapane KL, Murphy JB, et al. Effect of statin (HMG-Co-A-Reductase Inhibitor) use on 1-year mortality and hospitalization rates in older patients with cardioascular disease living in nursing homes. J Am Geriatr Soc 2002; 50(8): 1389–95PubMedCrossRef

52.

Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004; 117(11): 823–9PubMedCrossRef

53.

Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother 2006; 40(10): 1880–3PubMedCrossRef

54.

Agostini JV, Tinetti ME, Han L, et al. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc 2007; 55(3): 420–5PubMedCrossRef

55.

Bernick C, Katz R, Smith NL, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology 2005; 65(9): 1388–94PubMedCrossRef

56.

Summers MJ, Oliver KR, Coombes JS, et al. Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy 2007; 27(2): 183–90PubMedCrossRef

57.

Parale GP, Baheti NN, Kulkarni PM,et al. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol 2006; 62(4): 259–65PubMedCrossRef

58.

Winblad B, Jelic V, Kershaw P, et al. Effects of statins on cognitive function in patients with Alzheimer’s disease in galantamine clinical trials. Drugs Aging 2007; 24(1): 57–61PubMedCrossRef

59.

Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289(13): 1681–90PubMedCrossRef

60.

Maddrey WC. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol 2005; 39 (4 Suppl. 2): S83–9PubMedCrossRef

61.

Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324(17): 1149–55PubMedCrossRef

62.

Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346(8987): 1395–8PubMedCrossRef

63.

Tanne D, Haim M, Goldbourt U, et al. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke 2003; 34(3): 632–6PubMedCrossRef

64.

Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291(5): 565–75PubMedCrossRef

65.

Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354(15): 1567–77PubMedCrossRef

66.

Zoungas S, McGrath BP, Branley P, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006; 47(6): 1108–16PubMedCrossRef

67.

Spence D, Bang H, Chambless L, et al. Vitamin Intervention for Stroke Prevention trial: an efficacy analysis. Stroke 2005; 36: 2404–9PubMedCrossRef

68.

Bostom A, Seihub J, Jacques P, et al. Power shortage: clinical trials testing the “homocysteine hypothesis” against a background of folic acid fortified cereal grain flour. Ann Intern Med 2002; 137: 295–6

69.

Sato Y, Honda Y, Iwamoto J, et al. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 2005; 293(9): 1082–8PubMedCrossRef

70.

Ives S, Heuschmann P, Wolfe C, et al. Patterns of smoking cessation in the first 3 years after stroke: the South London Stroke Register. Eur J Cardiovasc Prev Rehabil 2008; 15: 329–35PubMedCrossRef

71.

Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 483S–512SPubMedCrossRef

72.

Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345(20): 1444–51PubMedCrossRef

73.

Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71–86CrossRef

74.

Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22(8): 983–8PubMedCrossRef

75.

Kammersgaard LP, Jorgensen HS, Reith J, et al. Short- and long-term prognosis for very old stroke patients. The Copenhagen Stroke Study. Age Ageing 2004; 33(2): 149–54PubMedCrossRef

76.

Bruggenjurgen B, Rossnagel K, Roll S, et al. The impact of atrial fibrillation on the cost of stroke: the Berlin Acute Stroke Study. Value Health 2007; 10(2): 137–43PubMedCrossRef

77.

Luengo-Fernandez R, Gray AM, Rothwell PM. Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom. Stroke 2006; 37(10): 2579–87PubMedCrossRef

78.

Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285(22): 2864–70PubMedCrossRef

79.

Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003; 290(8): 1049–56PubMedCrossRef

80.

Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131(7): 492–501PubMed

81.

European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–62

82.

Singer D, Albers GW, Dalen J, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest 2008; 133: 546S–92SPubMedCrossRef

83.

van Walraven C, Hart R, Singer D, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288: 2441–8PubMedCrossRef

84.

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449–57

85.

Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials. Arch Intern Med 1997; 157: 1237–40CrossRef

86.

Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349(11): 1019–26PubMedCrossRef

87.

Bayer. Randomized, double-blind study comparing once daily oral rivaroxaban with adjusted-dose oral warfarin for the prevention of stroke in subjects with non-valvular atrial fibrillation [ClinicalTrials.gov identifier NCT00403767]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Feb 24]

88.

Bristol-Myers Squibb. Apixaban for the prevention of stroke in subjects with atrial fibrillation [ClinicalTrials.gov identifier NCT00412984]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Feb 24]

89.

Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367(9526): 1903–12PubMedCrossRef

90.

Sanofi-aventis Bristol-Myers Squibb. Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00249795 [Accessed 2007 Dec 17]

91.

Andersen KK, Olsen TS. Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants: results from a Danish quality-control registry of 22,179 patients with ischemic stroke. Stroke 2007; 38(2): 259–63PubMedCrossRef

92.

Fornari LS, Calderaro D, Nassar IB, et al. Misuse of antithrombotic therapy in atrial fibrillation patients: frequent, pervasive and persistent. J Thromb Thrombolysis 2007; 23(1): 65–71PubMedCrossRef

93.

Hylek EM, D’Antonio J, Evans-Molina C, et al. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006; 37(4): 1075–80PubMedCrossRef

94.

Gage BF, Birman-Deych E, Kerzner R, et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005; 118(6): 612–7PubMedCrossRef

95.

Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998; 339(20): 1415–25PubMedCrossRef

96.

Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351(9113): 1379–87

97.

Mayberg MR, Wilson SE, Yatsu F, et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid Stenosis. Veterans Affairs Co-operative Studies Program 309 Trialist Group. JAMA 1991; 266(23): 3289–94PubMedCrossRef

98.

Rothwell PM, Eliasziw M, Gutnikov SA, et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363(9413): 915–24PubMedCrossRef

99.

Wennberg D, Lucas F, Birkmeyer J, et al. Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics. JAMA 1998; 279: 1278–81PubMedCrossRef

100.

Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995; 273(18): 1421–8

101.

Hobson 2nd RW, Weiss DG, Fields WS, et al. Efficacy of carotid endarterectomy for asymptomatic carotid Stenosis. The Veterans Affairs Cooperative Study Group. N Engl J Med 1993; 328(4): 221–7PubMedCrossRef

102.

Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363(9420): 1491–502PubMedCrossRef

103.

Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2006; 113(24): e873–923PubMedCrossRef

104.

Bond R, Rerkasam K, Cuffe R, et al. A systematic review of the associations between age and sex and the operative risks of carotid endarterectomy. Cerebrovasc Dis 2005; 20: 69–77PubMedCrossRef

105.

Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006; 355(16): 1660–71PubMedCrossRef

106.

Ringleb PA, Allenberg J, Bruckmann H, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006; 368(9543): 1239–47PubMedCrossRef

107.

Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004; 351(15): 1493–501PubMedCrossRef

108.

Kastrup A, Schulz JB, Raygrotzki S, et al. Comparison of angioplasty and stenting with cerebral protection versus endarterectomy for treatment of internal carotid artery stenosis in elderly patients. J Vasc Surg 2004; 40(5): 945–51PubMedCrossRef

109.

Hobson 2nd RW, Howard VJ, Roubin GS, et al. Carotid artery stenting is associated with increased complications in octogenarians: 30-day stroke and death rates in the CREST lead-in phase. J Vasc Surg 2004; 40(6): 1106–11PubMedCrossRef

110.

Lam RC, Lin SC, DeRubertis B, et al. The impact of increasing age on anatomic factors affecting carotid angioplasty and stenting. J Vasc Surg 2007; 45(5): 875–80PubMedCrossRef

111.

Handler SM, Wright RM, Ruby CM, et al. Epidemiology of medication-related adverse events in nursing homes. Am J Geriatr Pharmacother 2006; 4(3): 264–72PubMedCrossRef

112.

Budnitz D, Shehab N, Kegler S, et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007; 147: 755–65PubMed

113.

Hoffler K, Morgenstern H. Age dependence of therapy result and risk in the treatment of arterial hypertension. J Cardiovasc Pharmacol 1990; 16(Suppl. 5): S184–8PubMed

114.

Edoute Y, Nagachandran P, Svirski B, et al. Cardiovascular adverse drug reaction associated with combined beta-adrenergic and calcium entry-blocking agents. J Cardiovasc Pharmacol 2000; 35: 556–9PubMedCrossRef

115.

Graves T, Hanlon JT, Schmader KE, et al. Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med 1997; 157(19): 2205–10PubMedCrossRef

116.

Lindh J, Holm L, Dahl M, et al. Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis 2008; 25: 151–9PubMedCrossRef

117.

Beyth R, Landefeld C. Anticoagulants in older patients: a safety perspective. Drugs Aging 1995; 6: 45–54PubMedCrossRef

118.

Gamaldo A, Moghekar A, Kilada S, et al. Effect of a clinical stroke on the risk of dementia in a prospective cohort. Neurology 2006; 67(8): 1363–9PubMedCrossRef

119.

Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277(10): 813–7PubMedCrossRef

120.

Regan C, Katona C, Walker Z, et al. Relationship of vascular risk to the progression of Alzheimer disease. Neurology 2006; 67(8): 1357–62PubMedCrossRef

121.

McCarron MO, Nicoll JA. Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. Lancet Neurol 2004; 3(8): 484–92PubMedCrossRef

122.

Ritter MA, Droste DW, Hegedus K, et al. Role of cerebral amyloid angiopathy in intracerebral hemorrhage in hypertensive patients. Neurology 2005; 64(7): 1233–7PubMedCrossRef

123.

Kandzari DE, Granger CB, Simoons ML, et al. Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). Am J Cardiol 2004; 93(4): 458–61PubMedCrossRef

124.

Leblanc R, Haddad G, Robitaille Y. Cerebral hemorrhage from amyloid angiopathy and coronary thrombolysis. Neurosurgery 1992; 31(3): 586–90PubMedCrossRef

125.

McCarron MO, Nicoll JA, Ironside JW, et al. Cerebral amyloid angiopathy-related hemorrhage. Interaction of APOE epsilon2 with putative clinical risk factors. Stroke 1999; 30(8): 1643–6PubMedCrossRef

126.

Sloan MA, Price TR, Petito CK, et al. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. Neurology 1995; 45(4): 649–58PubMedCrossRef

127.

Walker D, Broderick D, Kotsenas A, et al. Routine use of gradient-echo MRI to screen for cerebral amyloid angiopathy in elderly patients. AJR Am J Roentgenol 2004; 182: 1547–50PubMed

128.

Tanko LB, Christiansen C, Cox DA, et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005; 20(11): 1912–20PubMedCrossRef

129.

Yavuzer G, Ataman S, Suldur N, et al. Bone mineral density in patients with stroke. Int J Rehabil Res 2002; 25(3): 235–9PubMedCrossRef

130.

Sato Y, Iwamoto J, Kanoko T, et al. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 2005; 64(5): 811–6PubMedCrossRef

131.

Sato Y, Iwamoto J, Kanoko T, et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005; 165(15): 1743–8PubMedCrossRef

132.

Beaupre GS, Lew HL. Bone-density changes after stroke. Am J Phys Med Rehabil 2006; 85(5): 464–72PubMedCrossRef

133.

Poole KE, Reeve J, Warburton EA. Falls, fractures, and osteoporosis after stroke: time to think about protection? Stroke 2002; 33(5): 1432–6PubMedCrossRef

134.

Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclo-oxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345(25): 1809–17PubMedCrossRef

135.

Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with Ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 2007; 66(6): 764–70PubMedCrossRef

136.

Linden T, Blomstrand C, Skoog I. Depressive disorders after 20 months in elderly stroke patients: a case-control study. Stroke 2007; 38(6): 1860–3PubMedCrossRef

137.

Weinrieb RM, Auriacombe M, Lynch KG, et al. Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Saf 2005; 4(2): 337–44PubMedCrossRef

138.

Ament P, Bertolino J, Liszewski J. Clinically significant drug interactions. Am Fam Physician 2000; 61: 1745–54PubMed

139.

Bhogal SK, Teasell R, Foley N, et al. Heterocyclics and selective serotonin reuptake inhibitors in the treatment and prevention of poststroke depression. J Am Geriatr Soc 2005; 53(6): 1051–7PubMedCrossRef

140.

van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 323(7314): 655–8PubMedCrossRef

141.

Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract 2005; 59(10): 1210–7PubMedCrossRef

142.

Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105(12): 1446–52PubMedCrossRef

143.

Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69(9): 904–10PubMedCrossRef

144.

Vollrath AM, Sinclair C, Hallenbeck J. Discontinuing cardiovascular medications at the end of life: lipid-lowering agents. J Palliat Med 2005; 8(4): 876–81PubMedCrossRef

145.

Stevenson J, Abernethy AP, Miller C, et al. Managing comorbidities in patients at the end of life. BMJ 2004; 329(7471): 909–12PubMedCrossRef

146.

Polk DM, Watson K. Hospital discharge treatments after an acute event: evidence for a systems approach to prevention. Coron Artery Dis 2006; 17(3): 239–41PubMedCrossRef

147.

Ovbiagele B, Saver JL, Fredieu A, et al. PROTECT: a coordinated stroke treatment program to prevent recurrent thromboembolic events. Neurology 2004; 63(7): 1217–22PubMedCrossRef

148.

Bushneil CD, Zimmer L, Schwamm L, et al. The Adherence evaluation After Ischemic Stroke Longitudinal (AVAIL) Registry: design, rationale, and baseline patient characteristics. Am Heart J. In press

149.

Smaha LA. The American Heart Association Get With The Guidelines program. Am Heart J 2004; 148 (5 Suppl.): S46–8PubMedCrossRef

Titel: Secondary Stroke Prevention Strategies for the Oldest Patients
Possibilities and Challenges
verfasst von: Cheryl D. Bushnell
Cathleen S. Colón-Emeric
Publikationsdatum: 01.03.2009
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 3/2009
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200926030-00003

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Physical and Mental Fatigue in Parkinson’s Disease

Value of a New Fixed-Combination Pack of Bisphosphonate, Calcium and Vitamin D in the Therapy of Osteoporosis

Feasibility of Chemoradiotherapy for Oesophageal Cancer in Elderly Patients Aged ≥75 Years

Optimal Dosing of Galantamine in Patients with Mild or Moderate Alzheimer’s Disease

Stage-Specific Therapy for Cancer of the Oesophagus